Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children

Zhang, Zhilun; Zhu, Xiao-feng; Wang, Xu; Liang, Miao; Sun, Jing; Liu, Yan; Gao, Zhicheng; Wu, Junyu; Dong, Xiao; Liu, Rong-Kai; Chen, Jiang-Ting; Zhang, Yuan-Quan; Wang, Wei; Zhang, Liping; Yin, Weidong

doi:10.1016/j.vaccine.2012.04.038

Cited by 13 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, in a double-blind, randomized controlled study, the interchangeability of a Chinese inactivated (Healive) and a European inactivated hepatitis A (Havrix) vaccine was investigated among Chinese children (303 healthy children) according to 0 and 6-month schedules. The study confirmed the interchangeability with no consequences on safety or immunogenicity [11].…”

Section: Hepatitis a Vaccinessupporting

confidence: 66%

Advances in hepatitis immunization (A, B, E)

Hendrickx¹,

Vorsters²,

Damme³

2012

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Follow-up of vaccinated individuals confirms the long-term protection offered by the hepatitis A as well as hepatitis B vaccines. Data confirm the safety and immunogenicity profile of both vaccines, also when used in patient groups. The first data on the hepatitis E vaccine look promising, but questions on cross-protection, long-term efficacy and safety and immunogenicity in pregnant women and children less than 2 years remain unanswered.

show abstract

Section: Hepatitis a Vaccinessupporting

confidence: 66%

Advances in hepatitis immunization (A, B, E)

Hendrickx¹,

Vorsters²,

Damme³

2012

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Post-marketing clinical studies demonstrated that the vaccine induced equal or similar immunogenicity with internationally used inactivated hepatitis A vaccines and were interchangeable for the course of HAV immunization in children. 8 Healive Ò also provided lasting protection in healthy individuals with 2-dose schedule and was effective in curbing outbreaks of hepatitis A with one single dose. 9 China is one of the world's few countries, in which both inactivated HA vaccine and live attenuated hepatitis A vaccine Figure 2.…”

Section: Discussionmentioning

confidence: 99%

Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Zhang

Zhu

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

In China, both inactivated hepatitis A (HA) vaccine and live attenuated HA vaccine are available. We conducted a trial to evaluate 5-year immune persistence induced by one dose of inactivated or live attenuated HA vaccines in children. Subjects with no HA vaccination history had randomly received one dose of inactivated or live attenuated HA vaccine at 18-60 months of age. Anti-HAV antibody concentrations were measured before vaccination and at the first, second, and fifth year after vaccination. Suspected cases of hepatitis A were monitored during the study period. A total of 332 subjects were enrolled and 182 provided evaluable serum samples at all planned time points. seropositive rate at 5 y was 85.9% in the inactivated HA vaccine group and 90.7% in the live attenuated HA vaccine group. GMCs were 76.3% mIU/ml (95% CI: 61.7 - 94.4) and 66.8mIU/ml (95% CI: 57.8 - 77.3), respectively. No significant difference in antibody persistence between 2 groups was found. No clinical hepatitis A case was reported. A single dose of an inactivated or live attenuated HA vaccine at 18-60 months of age resulted in high HAV seropositive rate and anti-HAV antibody concentrations that lasted for at least 5 y.

show abstract

“…21 It is feasible to complete a two-dose schedule of HepA-I using HepA-I from different manufacturers. [27][28][29] Immunogenicity following HepA vaccination…”

Section: Administration Of Hepatitis a Vaccinementioning

confidence: 99%

“… 21 It is feasible to complete a two-dose schedule of HepA-I using HepA-I from different manufacturers. 27 – 29 …”

Section: Administration Of Hepatitis a Vaccinementioning

confidence: 99%

Hepatitis A vaccination

Zhang

2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. The strategy of HepA vaccination varies in different countries and mainly includes vaccination among highrisk populations, regional childhood vaccination and universal childhood vaccination. The incidence of hepatitis A has decreased greatly in many countries in the last 30 y, but hepatitis A outbreaks frequently occur among high-risk populations and those who have not been covered by universal child vaccination programs in recent years. Disease surveillance and serosurveys are suggested to clarify the shift in the epidemiology of hepatitis A. The long-term persistence of immune protection after one dose of HepA should be further studied, as well as the cost-effective evaluation of different strategies of HepA vaccination. Based on this evidence, the recommendation on HepA vaccination should be put forward scientifically and updated in a timely and well-implemented manner.

show abstract

Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children

Cited by 13 publications

References 11 publications

Advances in hepatitis immunization (A, B, E)

Advances in hepatitis immunization (A, B, E)

Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Hepatitis A vaccination

Contact Info

Product

Resources

About